# Universal Health Realty Income Trust: financial statements, quarterly

UHT · NYSE · CIK 798783 · [Real estate](/sectors/real-estate.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/uht.md) · [Financials](/companies/uht/financials.md) · [Filings](/companies/uht/filings.md) · [Insiders](/companies/uht/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/uht/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [24.2](/filings/0000950170-24-124121.md) | [24.3 d](/filings/0001193125-26-071594.md) | [25.1](/filings/0000950170-25-067009.md) | [24.7](/filings/0001193125-25-177000.md) | [24.5](/filings/0001193125-25-272382.md) | [24.6 d](/filings/0001193125-26-071594.md) | [24.5](/filings/0001193125-26-211984.md) | [24.9](/filings/0001193125-26-340281.md) | [25.3](/filings/0001193125-25-272382.md) | [24.5 d](/filings/0001193125-26-071594.md) | [24.5](/filings/0001193125-26-211984.md) | [25.0](/filings/0001193125-26-340281.md) |
| Operating income | $m | [8.0](/filings/0000950170-24-124121.md) | [8.2 d](/filings/0001193125-26-071594.md) | [9.5](/filings/0000950170-25-067009.md) | [9.6](/filings/0001193125-25-177000.md) | [8.5](/filings/0001193125-25-272382.md) | [9.3 d](/filings/0001193125-26-071594.md) | [9.0](/filings/0001193125-26-211984.md) | [8.8](/filings/0001193125-26-340281.md) | [8.4](/filings/0001193125-25-272382.md) | [8.5 d](/filings/0001193125-26-071594.md) | [9.0](/filings/0001193125-26-211984.md) | [9.2](/filings/0001193125-26-340281.md) |
| Interest expense | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Net income | $m | [3.9](/filings/0000950170-24-124121.md) | [3.6 d](/filings/0001193125-26-071594.md) | [5.3](/filings/0000950170-25-067009.md) | [5.3](/filings/0001193125-25-177000.md) | [4.0](/filings/0001193125-25-272382.md) | [4.7 d](/filings/0001193125-26-071594.md) | [4.8](/filings/0001193125-26-211984.md) | [4.5](/filings/0001193125-26-340281.md) | [4.0](/filings/0001193125-25-272382.md) | [4.3 d](/filings/0001193125-26-071594.md) | [5.0](/filings/0001193125-26-211984.md) | [5.9](/filings/0001193125-26-340281.md) |
| Diluted EPS | $ per share | [0.28](/filings/0000950170-24-124121.md) | not reported | [0.38](/filings/0000950170-25-067009.md) | [0.38](/filings/0001193125-25-177000.md) | [0.29](/filings/0001193125-25-272382.md) | not reported | [0.34](/filings/0001193125-26-211984.md) | [0.32](/filings/0001193125-26-340281.md) | [0.29](/filings/0001193125-25-272382.md) | not reported | [0.36](/filings/0001193125-26-211984.md) | [0.43](/filings/0001193125-26-340281.md) |
| Basic EPS | $ per share | [0.28](/filings/0000950170-24-124121.md) | not reported | [0.38](/filings/0000950170-25-067009.md) | [0.38](/filings/0001193125-25-177000.md) | [0.29](/filings/0001193125-25-272382.md) | not reported | [0.35](/filings/0001193125-26-211984.md) | [0.33](/filings/0001193125-26-340281.md) | [0.29](/filings/0001193125-25-272382.md) | not reported | [0.36](/filings/0001193125-26-211984.md) | [0.43](/filings/0001193125-26-340281.md) |

- Revenue: us-gaap:Revenues
- Operating income: us-gaap:OperatingIncomeLoss
- Interest expense: not reported
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [8.4](/filings/0000950170-23-061157.md) | [8.2](/filings/0000950170-25-027861.md) | [7.7](/filings/0000950170-24-055718.md) | [5.6](/filings/0000950170-24-094044.md) | [6.4](/filings/0000950170-24-124121.md) | [7.1](/filings/0001193125-26-071594.md) | [7.0](/filings/0000950170-25-067009.md) | [6.6](/filings/0001193125-25-177000.md) | [6.9](/filings/0001193125-25-272382.md) | [6.7](/filings/0001193125-26-340281.md) | [7.1](/filings/0001193125-26-211984.md) | [6.8](/filings/0001193125-26-340281.md) |
| Total assets | $m | [608](/filings/0000950170-23-061157.md) | [596](/filings/0000950170-25-027861.md) | [596](/filings/0000950170-24-055718.md) | [587](/filings/0000950170-24-094044.md) | [584](/filings/0000950170-24-124121.md) | [581](/filings/0001193125-26-071594.md) | [573](/filings/0000950170-25-067009.md) | [573](/filings/0001193125-25-177000.md) | [568](/filings/0001193125-25-272382.md) | [565](/filings/0001193125-26-340281.md) | [564](/filings/0001193125-26-211984.md) | [567](/filings/0001193125-26-340281.md) |
| Total liabilities | $m | [398](/filings/0000950170-23-061157.md) | [395](/filings/0000950170-25-027861.md) | [400](/filings/0000950170-24-055718.md) | [396](/filings/0000950170-24-094044.md) | [403](/filings/0000950170-24-124121.md) | [401](/filings/0001193125-26-071594.md) | [401](/filings/0000950170-25-067009.md) | [408](/filings/0001193125-25-177000.md) | [409](/filings/0001193125-25-272382.md) | [413](/filings/0001193125-26-340281.md) | [416](/filings/0001193125-26-211984.md) | [423](/filings/0001193125-26-340281.md) |
| Long-term debt | $m | not reported | [360](/filings/0000950170-24-021191.md) | not reported | not reported | not reported | [368](/filings/0000950170-25-027861.md) | not reported | not reported | not reported | [375](/filings/0001193125-26-071594.md) | not reported | not reported |
| Shareholders' equity | $m | [210](/filings/0000950170-23-061157.md) | [201](/filings/0000950170-25-027861.md) | [196](/filings/0000950170-24-055718.md) | [191](/filings/0000950170-24-094044.md) | [182](/filings/0000950170-24-124121.md) | [180](/filings/0001193125-26-071594.md) | [172](/filings/0000950170-25-067009.md) | [165](/filings/0001193125-25-177000.md) | [159](/filings/0001193125-25-272382.md) | [152](/filings/0001193125-26-340281.md) | [148](/filings/0001193125-26-211984.md) | [144](/filings/0001193125-26-340281.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Total assets: us-gaap:Assets
- Total liabilities: us-gaap:Liabilities
- Long-term debt: us-gaap:LongTermDebt
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [10.2 d](/filings/0000950170-24-124121.md) | [10.5 d](/filings/0001193125-26-071594.md) | [11.7](/filings/0000950170-25-067009.md) | [12.1 d](/filings/0001193125-25-177000.md) | [9.9 d](/filings/0001193125-25-272382.md) | [13.2 d](/filings/0001193125-26-071594.md) | [11.6](/filings/0001193125-26-211984.md) | [13.7 d](/filings/0001193125-26-340281.md) | [10.2 d](/filings/0001193125-25-272382.md) | [13.6 d](/filings/0001193125-26-071594.md) | [12.0](/filings/0001193125-26-211984.md) | [12.4 d](/filings/0001193125-26-340281.md) |
| Capital expenditure | $m | not reported | [0.0 d](/filings/0001193125-26-071594.md) | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Dividends paid | $m | [9.9](/filings/0000950170-24-124121.md) | [10.0 d](/filings/0001193125-26-071594.md) | [10.0](/filings/0000950170-25-067009.md) | [10.2](/filings/0001193125-25-177000.md) | [10.1](/filings/0001193125-25-272382.md) | [10.2 d](/filings/0001193125-26-071594.md) | [10.2](/filings/0001193125-26-211984.md) | [10.3](/filings/0001193125-26-340281.md) | [10.3](/filings/0001193125-25-272382.md) | [10.3 d](/filings/0001193125-26-071594.md) | [10.3](/filings/0001193125-26-211984.md) | [10.5](/filings/0001193125-26-340281.md) |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
- Dividends paid: us-gaap:PaymentsOfDividends

## Shares

| Line item | Unit | Q3 FY2022 (2022-09-30) | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [13.8](/filings/0000950170-23-061157.md) | [13.8](/filings/0000950170-24-055718.md) | [13.8](/filings/0000950170-24-094044.md) | [13.8](/filings/0000950170-24-124121.md) | [13.8](/filings/0000950170-25-067009.md) | [13.8](/filings/0001193125-25-177000.md) | [13.8](/filings/0001193125-25-272382.md) | [13.9](/filings/0001193125-26-211984.md) | [13.9](/filings/0001193125-26-340281.md) | [13.9](/filings/0001193125-25-272382.md) | [13.9](/filings/0001193125-26-211984.md) | [13.9](/filings/0001193125-26-340281.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 13,898,684 at 2026-07-31, from the cover of the [10-Q filed 2026-08-07](/filings/0001193125-26-340281.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:24 ET. No prices; not investment advice.